Duhn Therapeutics inks license deal with OM Pharma

23 October 2024

France-based clinical-stage biotech Duhn Therapeutics (which is co-founded by Landmark BioVentures) and Swiss firm OM Pharma announced an exclusive license agreement to advance a pipeline of lipid-based cancer immunotherapies.

Duhn Therapeutics, with executive management support from Landmark BioVentures, an integrated and agile biotech hub-and-spoke company, will advance its lead program, DHN198, for solid cancers associated with or resulting from chronic non-resolved immunosuppressive inflammation.

Within the agreement, OM Pharma grants Duhn Therapeutics global and exclusive rights to develop and commercialize DHN198. OM Pharma will be entitled to equity rights in Duhn Therapeutics, as well as up to double-digit royalties on net sales. OM Pharma may also receive up to 100 million Swiss fracs ($116.5 million) in development and commercial milestones from Duhn Therapeutics.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK